Markets
Dickens, Great Expectations, and lay on the floor
Vintage engraving of a scene from Great Expectations / how Micron investors are feeling. (Illustration by F. A. Fraser/Getty Images)

Micron blew the lights out on earnings, so why is the stock dropping?

After a relentless rise into the print, a stunning beat — 21% on revenue and 36% on adjusted EPS — wasn't quite enough to keep the momentum going.

For a company of its size, Micron delivered one of the most stunning beats in recent memory yesterday, with shades of Nvidia in the early days of the AI boom, as revenue came in 21% ahead of Bloomberg-compiled analysts' estimates, and adjusted EPS beat by 36%.

Indeed, as our colleague Luke Kawa pointed out, the "AI growth torch passed from GPUs to memory" with Micron notching 196% annual revenue growth in Q2.

And yet, as of 6:52 a.m. ET, Micron is trading a touch over $435 a share, down more than 5% on yesterday's closing price. Fellow memory stock peer Sandisk isn't faring any better, down 5.4%.

Some pundits on Wall Street might rush to point out higher capex spending and minimal further upside to gross margins as reasons that the stock is in the red. And while it is true that Micron now expects capital spending to exceed $25 billion this fiscal year — analysts had only forecasted $22.4 billion — it takes some remarkable gymnastics to believe that a ~10% capex bump is the reason for softness in the share price, especially when the company’s also forecasted Q3 revenue of $33.5 billion at the midpoint of its range, some 41% ahead of the $23.7 billion analyst estimate.

A simpler explanation is that red-hot Micron has roughly doubled since mid-December, has risen 283% since July 1st of last year, is now bigger than Netflix and Costco, and that the buy-side's expectations were just maybe a little more elevated than those on the sell-side.

Micron and sandisk returns
Sherwood News

Longer-term concerns about how long the memory supply crunch might last, and whether Micron can sign more multi-year deals (the company only signed one, so far) could also be playing on the minds of investors. And, of course, it doesn't help that equities generally got hammered yesterday as concerns about inflation and the global supply of oil weighed on risk assets.

More Markets

See all Markets
markets

Uber will invest $1.25 billion in Rivian in a new robotaxi deal

EV maker Rivian surged up more than 9% in premarket trading on Thursday following an announcement that Uber will invest up to $1.25 billion in the company through 2031 as part of a robotaxi partnership.

The deal will begin with an initial $300 million investment, and Uber will purchase 10,000 autonomous versions of the R2. Uber will have the option to buy 40,000 more in 2030.

The R2 is Rivian's smaller, less-expensive model and is set to roll out to buyers in the second quarter of this year.

Uber, which has more than 20 autuonomous vehicle partnerships ranging from Alphabet’s Waymo to Baidu, has become a dominant robotaxi force.

Rivian had first hinted at robotaxi plans at its “Autonomy and AI Day” in December.

The R2 is Rivian's smaller, less-expensive model and is set to roll out to buyers in the second quarter of this year.

Uber, which has more than 20 autuonomous vehicle partnerships ranging from Alphabet’s Waymo to Baidu, has become a dominant robotaxi force.

Rivian had first hinted at robotaxi plans at its “Autonomy and AI Day” in December.

markets

Lilly reports encouraging trial results for its next-gen GLP-1 shot

Eli Lilly released late-stage trial results for its next-generation GLP-1 shot, retatrutide, showing the drug helped patients lose more weight than anything currently on the market.

Patients taking the highest dose of retatrutide, 12 mg, lost 16.8% of their body weight after 40 weeks, more than its current best-seller, tirzepatide. The results also showed significant reduction in blood sugar levels.

The stock was flat in premarket trading following the news.

Lilly's tirzepatide, sold under the brand names Zepbound and Mounjaro, is currently the most-sold drug in the world. The company's sales have now outpaced its top-rival, Novo Nordisk, which was the first to bring a GLP-1 to market but has seen sales decelerate as competitors have muscled in.

Still, some expect Lilly's winning streak may not last forever. Analysts at HSBC gave the stock a rare downgrade earlier this week, citing a crowded market among other factors.

markets

Gold and silver dip amid inflation concerns and ongoing Iran war

Often seen as safe havens through times of uncertainty, precious metals aren't proving that way today, as oil prices spike amid escalations in the Iran war, compounding inflationary concerns and sending the SPDR Gold Shares ETF and iShares Silver Trust down 3.4% and 6.6%, respectively, at 6:55 a.m. ET.

Although the Fed kept rates steady yesterday, as was universally expected, officials raised their forecasts for inflation — a move which seems to have spooked investors, who had already been taking risk off the table in recent weeks. With Brent crude north of $114 per barrel this morning, investors look to be bracing for further inflationary shock and are dumping gold and silver, as implied odds of a Fed rate cut in June plummeted on prediction markets from 60% on February 23rd, to just 16% this morning.

The shiny metal slump is already weighing on mining stocks like Anglogold Ashanti, Newmont, Wheaton Precious Metals, and Agnico Eagle, which are all plunging in premarket trading.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Derivatives, LLC, or Robinhood Money, LLC. Futures and event contracts are offered through Robinhood Derivatives, LLC.